Auspex Pharmaceuticals Overview

  • Founded
  • 2001
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 37
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $3.5B
Latest Deal Amount

Auspex Pharmaceuticals General Information

Description

Developer of deuterated analogs of clinically-validated drugs. The company develops a pipeline of therapeutics that improves on existing drugs across various therapeutic areas. It focuses on the development of drugs for the treatment of involuntary movement disorders, respiratory disease and inflammation.

Contact Information

Website
www.auspexpharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Acquirer
Teva Pharmaceutical Industries
Primary Office
  • 3366 North Torrey Pines Court
  • Suite 225
  • San Diego, CA 92037
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Auspex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 05-May-2015 $3.5B 00000 00.00 Completed Clinical Trials - Phase 3
15. 2PO 23-Jan-2015 00000 00000 Completed Clinical Trials - Phase 3
14. 2PO 11-Jul-2014 000.00 00000 00000 Completed Clinical Trials - Phase 3
13. IPO 05-Feb-2014 0000 00000 00000 Completed Clinical Trials - Phase 3
12. Debt - General 08-Jan-2014 0000 00000 Completed Clinical Trials - Phase 3
11. Later Stage VC (Series E) 20-Dec-2013 000.00 00000 00000 Completed Clinical Trials - Phase 3
10. Later Stage VC (Series D) 06-Sep-2013 0000 0000 000.00 Completed Clinical Trials - Phase 3
9. Debt - General 11-Mar-2013 0000 Completed Clinical Trials - Phase 3
8. Later Stage VC 09-Nov-2012 $19M $70M Completed Clinical Trials - Phase 3
7. Later Stage VC 28-Dec-2011 $3M $51M Completed Generating Revenue
To view Auspex Pharmaceuticals’s complete valuation and funding history, request access »

Auspex Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series E 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A5 00,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A4 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A3 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A2 610,294 $0.000100 8% $1.7 $1.7 1x $1.7 0.87%
Series A1 613,500 $0.000100 8% $1 $1 1x $1 0.88%
To view Auspex Pharmaceuticals’s complete cap table history, request access »

Auspex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of deuterated analogs of clinically-validated drugs. The company develops a pipeline of therapeutics that impr
Drug Discovery
San Diego, CA
37 As of 2014
00000
0.00 0000-00-00
000000&0 00000

000 0000

at nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserun
0000 000000000
Pudong, China
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

0000 000

im veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis a
0000 000000000
San Diego, CA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Auspex Pharmaceuticals Competitors (77)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Hua Medicine Formerly VC-backed Pudong, China 000 00000 00000000 00000
0000 000000 Formerly VC-backed San Diego, CA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 000000&0
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
You’re viewing 5 of 77 competitors. Get the full list »

Auspex Pharmaceuticals Patents

  • 600

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 27

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Auspex Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3893876-A1 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Pending 13-Dec-2018 00000000000
AU-2019395250-A1 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Pending 13-Dec-2018 00000000000
US-20200188371-A1 Methods for the treatment of dyskinesia in cerebral palsy Pending 13-Dec-2018 00000000000
CA-3123393-A1 Deutetrabenazine for the treatment of dyskinesia in cerebral palsy Pending 13-Dec-2018 00000000000
US-20200016148-A1 Analogs of deutetrabenazine, their preparation and use Granted 15-Mar-2017 A61K31/4745
To view Auspex Pharmaceuticals’s complete patent history, request access »

Auspex Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Auspex Pharmaceuticals Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioMed Ventures Corporate Venture Capital Minority 000 0000 000000 0
Costa Verde Capital Venture Capital Minority 000 0000 000000 0
Deerfield Management Venture Capital Minority 000 0000 000000 0
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
Panorama Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial